help | sitemap

 

 

 

 

Fraudulent offers of employment with Novartis

 It has come to our attention that an unknown individual or company is randomly emailing individuals offering them employment with Novartis.

Some of the email attachments also make use of the Novartis logo and the Novartis address, in an attempt to authenticate the e-mail.

Novartis are very concerned about the fraudulent use of our name and logo. Novartis does not offer any position without interviews and Novartis never asks candidates for money. Novartis is not associated in any way with such fraudulent offers.

In most instances the fraudulent e-mail has been accompanied by a range of  false documents such as an Appointment letter, Terms & Contract agreement and UK Visa Clearance form, asking the recipient to provide personal details on questionnaires purporting to come from the UK Immigration authorities. In some cases the recipient has also been asked to supply money.

Novartis do not yet know the identity of those fraudulently making use of Novartis details, and have referred the matter to the relevant authorities.

In the meantime please be vigilant and do not supply any money or personal details in response to these false offers. If you receive such e-mails you should forward them to the UK Press Office – pressoffice-UK.phgbfr@novartis.com 

 
 

About Novartis

Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world.  This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz. 

Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. 

 

Careers at Novartis

A performance oriented company, we enjoy a fast moving, goal oriented environment with excellent opportunities for career development both in the UK and internationally.

 
 

Patients and Carers

For comprehensive information about common medical conditions, your medication and other health concerns.

 

Investors

SWX

 
 

 

NOVZn

 

 
 

 

NVS

 

 
Novartis shipped 66m malaria treatments to patients in developing countries which contributed to saving an estimated 450,000 lives
 
Since 2000, more than 4.5 million people with leprosy have been treated through the use of multi-drug therapy (MDT) supplied by Novartis.
 
 

Novartis.com

novartis

Please visit our global website, novartis.com, for more information about our company, people and products.

Novartis Drug Development Process

Novartis drug discovery and development efforts begin and end with the patient.

Novartis Oncology UK

Novartis Oncology aims to discover and develop innovative medicines that improve and extend the lives of people with cancer.